Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arijit Ganguli

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
European Urology|February 27, 2025
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK StudyStephen J Freedland, John P Mulhall, Martin Gleave, et al.
The Patient|August 11, 2023
Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UKJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
Clinical Medicine Insights. Oncology|April 1, 2026
Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective ReviewMatheus Sewastjanow-Silva, Mok Oh, Lawrence Chang, et al.
European Urology Focus|December 19, 2025
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and ChallengesNeal D Shore, Stephen J Freedland, Lisa G Horvath, et al.
The Prostate|June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroupsArnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
NEJM Evidence|February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate CancerStephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
European Urology|February 27, 2025
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK StudyStephen J Freedland, John P Mulhall, Martin Gleave, et al.
The Patient|August 11, 2023
Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UKJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
Clinical Medicine Insights. Oncology|April 1, 2026
Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective ReviewMatheus Sewastjanow-Silva, Mok Oh, Lawrence Chang, et al.
European Urology Focus|December 19, 2025
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and ChallengesNeal D Shore, Stephen J Freedland, Lisa G Horvath, et al.
The Prostate|June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroupsArnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
NEJM Evidence|February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate CancerStephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Pageof 7